BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 9191010)

  • 1. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker.
    Turner JR; Odze RD; Crum CP; Resnick MB
    Hum Pathol; 1997 Jun; 28(6):740-4. PubMed ID: 9191010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.
    Nortunen M; Huhta H; Helminen O; Parkkila S; Kauppila JH; Karttunen TJ; Saarnio J
    Virchows Arch; 2018 Nov; 473(5):567-575. PubMed ID: 30066203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma.
    Vermylen P; Roufosse C; Burny A; Verhest A; Bosschaerts T; Pastorekova S; Ninane V; Sculier JP
    Eur Respir J; 1999 Oct; 14(4):806-11. PubMed ID: 10573225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa.
    Going JJ; Keith WN; Neilson L; Stoeber K; Stuart RC; Williams GH
    Gut; 2002 Mar; 50(3):373-7. PubMed ID: 11839717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
    Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
    Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
    Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
    Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
    Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
    Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.
    Burjonrappa SC; Reddimasu S; Nawaz Z; Gao X; Sharma P; Loggie B
    Indian J Cancer; 2007; 44(1):1-5. PubMed ID: 17401217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
    Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
    Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.
    Hong MK; Laskin WB; Herman BE; Johnston MH; Vargo JJ; Steinberg SM; Allegra CJ; Johnston PG
    Cancer; 1995 Jan; 75(2):423-9. PubMed ID: 7812911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus.
    Stairs DB; Nakagawa H; Klein-Szanto A; Mitchell SD; Silberg DG; Tobias JW; Lynch JP; Rustgi AK
    PLoS One; 2008; 3(10):e3534. PubMed ID: 18953412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
    Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L; Goldman H; Odze RD
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
    Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
    Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.